Boston CEO 2026
November 2–3, 2026
Mandarin Oriental, Boston
Boston CEO 2026 took place November 2–3, 2026 at Mandarin Oriental, Boston. The next Boston CEO meeting is October 25–26, 2027.
Boston CEO 2026 brought together biopharma CEOs, heads of R&D, life science investors and leading academics for two days of off-the-record panels, fireside chats and networking. The program featured more than 140 speakers on R&D productivity, AI in drug discovery, regulatory strategy, dealmaking and capital formation, including fireside chats with Nobel laureates Phil Sharp and Bill Kaelin, Bob Langer and Tim Springer, and research leaders from Biogen, BMS, Novartis, Pfizer and EMD Serono.
Boston CEO 2026 Co-Hosts
Boston CEO 2026 was co-hosted alongside leaders in the industry.
Bill Meury
CEO
Incyte
Company 1
Bob Langer
Koch Institute Professor, MIT
Co-Founder, Moderna
Company 1
Christoph Westphal
General Partner, Longwood Fund
Founder/CEO, ALNY MNTA XLRN
Company 1
David Weinreich
Global Head, R&D
EMD Serono
Company 1
Fiona Marshall
President, Biomedical Research
Novartis
Company 1
Jane Grogan
Head, Research
Biogen
Company 2
Mathai Mammen
CEO
Parabilis
Company 2
Phil Sharp
Nobel laureate; Co-Founder, Alnylam/Biogen
Professor, MIT
Company 2
Robert Plenge
Chief Research Officer
BMS
Company 2
Featured Speakers
BioPharma CEOs
Laurent Levy
CEO
Nanobiotix
Company
Mathai Mammen
CEO
Parabilis
Company
Bill Meury
CEO
Incyte
Company
Jean-Frédéric Paulsen
CEO
Ferring Pharmaceuticals
Company
Tarek Rabah
President and CEO
Otsuka North America
Company
Research & Innovation Pioneers
Susan Hockfield
President Emerita
MIT
Company
Bill Kaelin
Nobel laureate
Professor, Dana-Farber Cancer Institute
Company
Bob Langer
Koch Institute Professor, MIT
Co-Founder, Moderna
Company
Phil Sharp
Nobel laureate; Co-Founder, Alnylam/Biogen
Professor, MIT
Company
Tim Springer
Lasker; Co-Founder, Moderna/Morphic
Professor, Harvard
Company
R&D Leaders
Jane Grogan
Head, Research
Biogen
Company
Jeff Legos
Chief Oncology Officer
Pfizer
Company
Fiona Marshall
President, Biomedical Research
Novartis
Company
Robert Plenge
Chief Research Officer
BMS
Company
David Weinreich
Global Head, R&D
EMD Serono
Company
Health System & Advocacy Leaders
Julian Adams
CEO
Stand Up To Cancer
Company
Jake Auchincloss
Congressman
Massachusetts
Company
Julie Gerberding
CEO, Foundation for the NIH
former Director, CDC
Company
John O'Brien
President and CEO
National Pharmaceutical Council
Company
Kevin Tabb
CEO
Beth Israel Lahey Health
Company
Pharma BD & Strategy Leaders
Andrew Baum
Senior Strategic Advisor
Pfizer
Company
Matt Hefner
Global Head, BD
Kyowa Kirin
Company
Christine Roth
Head, Global Product Strategy and Commercialization
Bayer Pharmaceuticals
Company
Tolga Tanguler
CCO
Alnylam
Company
Issei Tsukamoto
SVP, Head, BD
Astellas
Company
Blue-Chip Investors
Ari Brettman
Senior Managing Director
Blackstone Life Science
Company
Jeanne Cunicelli
President
UPMC Enterprises
Company
Raymond Kelleher
Managing Director
Cormorant
Company
Cailin McGurk
Managing Director
Morgan Stanley
Company
Jason Rhodes
Partner
Atlas Venture
Company
Program
Day 1
Selected topics
Biomedical Superintelligence & the Future of R&D
Accelerating Drug Discovery
Driving Productivity in R&D
Delivering the Next Generation of Diagnostics
Drug Approvals: Insights, Outlook, and Commitment to Patients
Bolstering the Regulatory Strategy
Targeted Licensing & Acquisitions
The Evolving Deal-Making Landscape
Capital Formation and Strategic Partnerships
Investor Outlook
Competing in a New Global Playing Field
Building Global BioPharmas
Biopharma Pipeline Sourcing
Crossroads of Science and Policy: Sustaining the Engine of Innovation
Translating Science into Medicine
Speakers and moderators
Julian Adams, Stand Up To Cancer · Reza Afkhami, Kamau Therapeutics · Nadim Ahmed, Cullinan Therapeutics · Manuel Aivado, Stelexis · Jeff Aronin, Paragon Biosciences · Annette Bakker, Children's Tumor Foundation · Aris Baras, Regeneron Genetics Center · Ron Batra, Dyne Therapeutics · Andrew Baum, Pfizer · Al Beardsley, Cirius Therapeutics · Laura Benjamin, Myris Therapeutics · Fawzi Benzaghou, formerly Ipsen · Michael Bierl, Flatiron Health · Peter Bisgaard, Pivotal Life Sciences · Eli Bixby, Cradle · Ari Brettman, Blackstone Life Science · John Butler, Akebia Therapeutics · Stewart Campbell, Novita Pharmaceuticals · Kara Carter, Viraccio Therapeutics · Abe Ceesay, Rapport Therapeutics · Judy Chou, AltruBio · Alexandria Cogdill, Daiichi Sankyo · Gavin Corcoran, Formation Bio · Christina Coughlin, Avacta Therapeutics · Jeanne Cunicelli, UPMC Enterprises · Rakhshita Dhar, Leaps by Bayer · Ashley Dombkowski, Cellics Therapeutics · Dipal Doshi, Entrada · Giulio Draetta, Orionis · Ruxandra Draghia-Akli, INTREPID Alliance · Tim Ehrlich, Gunderson Dettmer · Fiona Elwood, Janssen · Hannah England, Ropes & Gray · Julie Gerberding, Foundation for the NIH · Robbie Goldstein, Massachusetts Department of Public Health · Bruno Gomes, Roche · Vikas Goyal, Longwood Fund · Nenad Grmusa, DEM BioPharma · Jane Grogan, Biogen · Vera Grossmann, Foundation Medicine · Eran Harary, Remepy · Matt Hefner, Kyowa Kirin · Bill Heiden, MacroGenics · Andrew Hirsch, C4 Therapeutics · Susan Hockfield, MIT · Jacob Hooker, Sensorium Therapeutics · Bill Kaelin, Dana-Farber Cancer Institute · Vikram Karnani, Collegium Pharmaceutical · Anna Kazanchyan, Saghmos Therapeutics · Raymond Kelleher, Cormorant · Samir Khleif, Georgiamune · Yiannis Kiachopoulos, Causaly · Erin Kimbrel, Astellas · Isaac Klein, Dewpoint Therapeutics · Matt Klein, PTC Therapeutics · Anne Klibanski, Mass General Brigham · David Kolesky, MPM BioImpact · Olga Kolman, Servier · Seema Kumar, Cure. · Jeff Landau, Stipple Bio · Bob Langer, MIT · Kyle Lefkoff, Boulder Ventures · Jeff Legos, Pfizer · Francisco Leon, Tolerance Bio · Laurent Levy, Nanobiotix · Pedro Lichtinger, Starton Therapeutics · Michelle Longmire, Medable · Chris Loose, Progentos · Philippe Lopes-Fernandes, Ipsen · Jason Luke, Strand Therapeutics · Rick Lundberg, Eikonizo · Mathai Mammen, Parabilis · Brad Margus, Cerevance · Fiona Marshall, Novartis · Craig Martin, Orphan Therapeutics Accelerator · Sean McCarthy, CytomX · Murray McCutcheon, AbCellera · Wyatt McDonnell, Infinimmune · Cailin McGurk, Morgan Stanley · Kenneth Moch, Regerna Therapeutics · Kia Motesharei, ReAlta Life Sciences · Benjamin Moutier, AstraZeneca · Szabi Nagy, Turbine · Sekhar Naik, MResult · Kabir Nath, COMPASS Pathways · Adora Ndu, BridgeBio · Samar Noor, BMS · Tim Noyes, Newleos · John O’Brien, National Pharmaceutical Council · Gilmore O’Neill, Editas Medicine · Shinji Okitsu, Sanofi · Pini Orbach, Arkin Capital · Jean-Frédéric Paulsen, Ferring Pharmaceuticals · Rob Perez, Life Science Cares · Robert Plenge, BMS · Raj Prasad, CRISPR Therapeutics · Ferran Prat, BostonGene · Raviv Pryluk, PhaseV · Tarek Rabah, Otsuka North America · Aleks Radovic-Moreno, Longwood Fund · Chandra Ramanathan, BRC Therapeutics · Karen Reeves, Ligand · Scott Requadt, Prolium Bioscience · Jason Rhodes, Atlas Venture · David Roblin, Relation · Mike Rosenblatt, Flagship Pioneering · Christine Roth, Bayer Pharmaceuticals · Helen Sabzevari, Precigen · Karin Shanahan, BMS · Phil Sharp, MIT · Sarah Sheikh, Takeda · Brendan Smith, Weaver Biosciences · Tommy Sowers, UNC Chapel Hill · Tim Springer, Harvard · Joanna Stanicka, Axonis · Robert Stanislaro, FTI Consulting · Joe Stauffer, PVP Labs · Zhen Su, Marengo Therapeutics · Kevin Tabb, Beth Israel Lahey Health · Tolga Tanguler, Alnylam · Bharat Tewarie, Helio Genomics · Tamar Thompson, Alexion · Issei Tsukamoto, Astellas · Brent Vaughan, Eratos Therapeutics · Dennis Velasquez, Biorce · AJ Venkatakrishnan, nference · Jeffrey Venstrom, ClearNote Health · Rehan Verjee, Precede Bio · Cynthia Verst, IQVIA · Phil Vickers, Solu Therapeutics · Oliver Vince, Basecamp Research · Skip Virgin, Gates Foundation · Rogerio Vivaldi, Vesper Biotechnologies · Ming Wang, Phanes Therapeutics · Neil Warma, ProMIS Neurosciences · Anjli Warner, Arrowhead · David Weinreich, EMD Serono · Christoph Westphal, Longwood Fund · Robert Wild, Roche/Genentech · Leslie Williams, DaCapo Brainscience · Quin Wills, Ochre Bio · Richard Wilson, Astellas · Lilly Wollman, Synteny · Roman Yelensky, 10x Genomics · Samuel Zhang, Innovent
Day 2
7:00 am | Networking Breakfast
7:40 am | Biotech Market Update & Longwood Fund Introduction
Vikas Goyal, Partner, Longwood Fund
8:00 am | Building Global BioPharmas
Ashley Dombkowski, CEO, Cellics Therapeutics
Matt Klein, CEO, PTC Therapeutics
David Roblin, CEO, Relation
Samuel Zhang, CBO, Innovent
Moderator: Pedro Lichtinger, CEO, Starton Therapeutics
8:30 am | Drug Approvals: Insights, Outlook, and Commitment to Patients
Annette Bakker, CEO, Children's Tumor Foundation
Ron Batra, CSO, Dyne Therapeutics
Raviv Pryluk, CEO, PhaseV
Christine Roth, Head, Global Product Strategy and Commercialization, Bayer Pharmaceuticals
Moderator: Tamar Thompson, Head, Global Patient Experience, Alexion
9:00 am | Crossroads of Science and Policy: Sustaining the Engine of Innovation
Robbie Goldstein, Commissioner, Massachusetts Department of Public Health
Susan Hockfield, President Emerita, MIT
Tarek Rabah, President & CEO, Otsuka North America
Kevin Tabb, CEO, Beth Israel Lahey Health
Moderator: John O’Brien, President and CEO, National Pharmaceutical Council
9:30 am | Fireside Chat
Jane Grogan, Head, Research, Biogen
Jeff Legos, Chief Oncology Officer, Pfizer
Robert Plenge, Chief Research Officer, BMS
Moderator: Christoph Westphal, Founder/CEO/Lead Investor, Alnylam/Momenta/Acceleron
9:55 am | Networking Break
10:20 am | Prioritizing the Pipeline
Christina Coughlin, CEO, Avacta Therapeutics
Andrew Hirsch, CEO, C4 Therapeutics
Robert Wild, Global Head, Oncology Search & Evaluation, Roche/Genentech
Richard Wilson, SVP, Primary Focus Lead, Genetic Regulation, Astellas
Moderator: Dipal Doshi, CEO, Entrada
10:50 am | Advancing Late-Stage Assets
Stewart Campbell, CEO, Novita Pharmaceuticals
Abe Ceesay, CEO, Rapport Therapeutics
Anna Kazanchyan, CEO, Saghmos Therapeutics
Neil Warma, CEO, ProMIS Neurosciences
Moderator: Robert Stanislaro, Senior Managing Director, FTI Consulting
11:20 am | Managing the Runway
Chris Loose, CEO, Progentos
Joanna Stanicka, CEO, Axonis
Joe Stauffer, CMO, PVP Labs
Leslie Williams, CEO, DaCapo Brainscience
Moderator: Rick Lundberg, CEO, Eikonizo
11:50 am | CEO Chat: What it Takes to Build a Great Company
Mathai Mammen, CEO, Parabilis
Jean-Frédéric Paulsen, CEO, Ferring Pharmaceuticals
Moderator: Seema Kumar, CEO, Cure.
12:15 pm | Networking Luncheon
1:15 pm | Targeted Licensing & Acquisitions
Matt Hefner, Global Head, BD, Kyowa Kirin
Jeff Landau, CEO, Stipple Bio
Karen Reeves, SVP, Investments & Head, Clinical Strategy, Ligand
Anjli Warner, Head, BD & New Product Planning, Arrowhead
Moderator: Zhen Su, CEO, Marengo Therapeutics
1:45 pm | Accelerating Drug Discovery
Aris Baras, SVP, Head, Regeneron Genetics Center
Jacob Hooker, CEO, Sensorium Therapeutics
Szabi Nagy, CEO, Turbine
Phil Vickers, CEO, Solu Therapeutics
Moderator: Kara Carter, CEO, Viraccio Therapeutics
2:15 pm | Developing High-Performing Teams
Laura Benjamin, CEO, Myris Therapeutics
Nenad Grmusa, CEO, DEM BioPharma
Wyatt McDonnell, CEO, Infinimmune
Quin Wills, CEO, Ochre Bio
Lilly Wollman, CEO, Synteny
Moderator: Isaac Klein, President, Dewpoint Therapeutics
2:50 pm | Networking Break
3:15 pm | Positioning for Commercial Success
Michael Bierl, CBO, Flatiron Health
Kabir Nath, CEO, COMPASS Pathways
Karin Shanahan, EVP, Chief Supply Chain & Operations Officer, BMS
Dennis Velasquez, CCO, Biorce
Moderator: Vikram Karnani, CEO, Collegium Pharmaceutical
3:45 pm | Fireside Chat
Fiona Marshall, President, Biomedical Research, Novartis
David Weinreich, Global Head, R&D, EMD Serono
Moderator: Sekhar Naik, CEO, MResult
4:05 pm | The Evolving Deal-Making Landscape
Al Beardsley, CEO, Cirius Therapeutics
Hannah England, Partner, Ropes & Gray
Murray McCutcheon, SVP, Partnering, AbCellera
Issei Tsukamoto, SVP, Head, BD, Astellas
Moderator: Philippe Lopes-Fernandes, CBO, Ipsen
4:35 pm | Evaluating Investment Risk
Ari Brettman, Senior Managing Director, Blackstone Life Science
Cailin McGurk, Managing Director, Morgan Stanley
Pini Orbach, Managing Partner & Head, Pharma, Arkin Capital
Jason Rhodes, Partner, Atlas Venture
Moderator: Aleks Radovic-Moreno, Partner, Longwood Fund
5:00 pm | Cocktail Reception
2026 Agenda
Day 1
7:00 am | Networking Breakfast
7:40 am | Biotech Market Update & Longwood Fund Introduction
Christoph Westphal, GP, Longwood Fund; Founder/CEO, ALNY MNTA XLRN
8:00 am | Translating Science into Medicine
Laurent Levy, CEO, Nanobiotix
Michelle Longmire, CEO, Medable
Kia Motesharei, President & COO, ReAlta Life Sciences
Brendan Smith, CEO, Weaver Biosciences
Moderator: Kyle Lefkoff, General Partner, Boulder Ventures
8:30 am | Ecosystem of External Innovation
Nadim Ahmed, CEO, Cullinan Therapeutics
Jeanne Cunicelli, President, UPMC Enterprises
Anne Klibanski, CEO, Mass General Brigham
Scott Requadt, CEO, Prolium Bioscience
Moderator: Ferran Prat, CCO, BostonGene
9:00 am | Developing a Robust Pipeline
Giulio Draetta, Chief Strategy Officer, Orionis
Jason Luke, CMO, Strand Therapeutics
Helen Sabzevari, CEO, Precigen
Cynthia Verst, President, Design & Delivery Innovation, IQVIA
Moderator: Gilmore O’Neill, CEO, Editas Medicine
9:30 am | Fireside Chat: From Breakthrough to Blockbuster: Founding Biotech on Novel Science
Phil Sharp, Nobel laureate; Co-Founder, Alnylam/Biogen; Professor, MIT
Tim Springer, Lasker; Co-Founder, Moderna/Morphic; Professor, Harvard
Moderator: Christoph Westphal, Founder/CEO/Lead Investor, Alnylam/Momenta/Acceleron
9:50 am | Networking Break
10:15 am | R&D Collaboration
Eli Bixby, Co-Founder & Head, ML, Cradle
Alexandria Cogdill, Head, Strategic Initiatives, Global BD, Daiichi Sankyo
Julie Gerberding, CEO, Foundation for the NIH; former Director, CDC
Benjamin Moutier, SVP, Infectious Disease, AstraZeneca
Shinji Okitsu, Head, Research Strategic Collaborations & Partnerships, Sanofi
Moderator: Brad Margus, Chair, Cerevance; Chair, A-T Children’s Project
10:50 am | Delivering the Next Generation of Diagnostics
Julian Adams, CEO, Stand Up To Cancer
Vera Grossmann, Interim CEO, Foundation Medicine
Bharat Tewarie, CEO, Helio Genomics
Jeffrey Venstrom, CMO, ClearNote Health
Roman Yelensky, VP, Clinical Applications, 10x Genomics
Moderator: Rehan Verjee, CEO, Precede Bio
11:25 am | Competing in a New Global Playing Field
Judy Chou, CEO, AltruBio
Ruxandra Draghia-Akli, Chair, Scientific Advisory Board, INTREPID Alliance
Kenneth Moch, CEO, Regerna Therapeutics
Ming Wang, CEO, Phanes Therapeutics
Moderator: Raj Prasad, CFO, Crispr Therapeutics
11:55 am | Biomedical Superintelligence & the Future of R&D
Gavin Corcoran, EIR, Formation Bio; former CMO, Allergan
Olga Kolman, Head, US Emerging Portfolio Strategy, Servier
Samar Noor, Head, Clinical & Safety Data Insights & Analytics, BMS
Moderator: AJ Venkatakrishnan, SVP, AI, nference
12:15 pm | Networking Luncheon
1:00 pm | Fireside Chat: From Discovery to Medicine: Bringing Fundamental Science to Patients
Bill Kaelin, Nobel laureate; Professor, Dana-Farber Cancer Institute
Bob Langer, Koch Institute Professor, MIT; Co-Founder, Moderna
Moderator: Christoph Westphal, Founder/CEO/Lead Investor, Alnylam/Momenta/Acceleron
1:20 pm | Leveraging an Effective Board
Tim Noyes, CEO, Newleos
Rob Perez, Chair, Life Science Cares
Mike Rosenblatt, Senior Advisor, Flagship Pioneering; former CMO, Merck
Rogerio Vivaldi, Chair, Vesper Biotechnologies
Moderator: Bill Heiden, Chair, Macrogenics
1:50 pm | Biopharma Pipeline Sourcing
Bruno Gomes, Global Head, Oncology Research & Early Development, Roche
Erin Kimbrel, Head, Cell & Gene Therapy Research, Astellas
Francisco Leon, CEO, Tolerance Bio
Oliver Vince, COO, Basecamp Research
Moderator: Sekhar Naik, CEO, MResult
2:20 pm | Driving Productivity in R&D
Manuel Aivado, CEO, Stelexis
Fiona Elwood, VP, Disease Area Stronghold Lead, Neurodegeneration, Janssen
Samir Khleif, CEO, Georgiamune
Sarah Sheikh, Head, Global Development & SVP, Neuroscience, Takeda
Moderator: Yiannis Kiachopoulos, CEO, Causaly
2:50 pm | Networking Break
3:10 pm | Bolstering the Regulatory Strategy
Andrew Baum, Senior Strategic Advisor, Pfizer
Fawzi Benzaghou, former Global Head, Oncology, Ipsen & former CMO, Parabilis
Adora Ndu, Chief Regulatory Affairs Officer, BridgeBio
Tolga Tanguler, CCO, Alnylam
Moderator: Chandra Ramanathan, EVP, Commercialization & Strategy, BRC Therapeutics
3:40 pm | Capital Formation and Strategic Partnerships
Reza Afkhami, CBO, Kamau Therapeutics
Jeff Aronin, CEO, Paragon Biosciences
John Butler, CEO, Akebia Therapeutics
Sean McCarthy, CEO, CytomX
Moderator: Tim Ehrlich, Partner, Gunderson Dettmer
4:10 pm | Expanding upon the Potential of Scientific Innovation
Eran Harary, CMO, Remepy
Craig Martin, CEO, Orphan Therapeutics Accelerator
Tommy Sowers, Vice Chancellor, Innovation, Entrepreneurship & Economic Development, UNC Chapel Hill
Brent Vaughan, CEO, Eratos Therapeutics
Moderator: Skip Virgin, Head, AI Enabled Cures Frontiers, Gates Foundation
4:40 pm | Investor Outlook
Peter Bisgaard, Managing Director, Pivotal Life Sciences
Rakhshita Dhar, Head, Healthcare Investments, Leaps by Bayer
Raymond Kelleher, Managing Director, Cormorant
David Kolesky, Principal, MPM BioImpact
Moderator: Vikas Goyal, Partner, Longwood Fund
Day 2
7:00 am | Networking Breakfast
7:40 am | Biotech Market Update & Longwood Fund Introduction
Vikas Goyal, Partner, Longwood Fund
8:00 am | Building Global BioPharmas
Ashley Dombkowski, CEO, Cellics Therapeutics
Matt Klein, CEO, PTC Therapeutics
David Roblin, CEO, Relation
Samuel Zhang, CBO, Innovent
Moderator: Pedro Lichtinger, CEO, Starton Therapeutics
8:30 am | Drug Approvals: Insights, Outlook, and Commitment to Patients
Annette Bakker, CEO, Children's Tumor Foundation
Ron Batra, CSO, Dyne Therapeutics
Raviv Pryluk, CEO, PhaseV
Christine Roth, Head, Global Product Strategy and Commercialization, Bayer Pharmaceuticals
Moderator: Tamar Thompson, Head, Global Patient Experience, Alexion
9:00 am | Crossroads of Science and Policy: Sustaining the Engine of Innovation
Robbie Goldstein, Commissioner, Massachusetts Department of Public Health
Susan Hockfield, President Emerita, MIT
Tarek Rabah, President & CEO, Otsuka North America
Kevin Tabb, CEO, Beth Israel Lahey Health
Moderator: John O’Brien, President and CEO, National Pharmaceutical Council
9:30 am | Fireside Chat
Jane Grogan, Head, Research, Biogen
Jeff Legos, Chief Oncology Officer, Pfizer
Robert Plenge, Chief Research Officer, BMS
Moderator: Christoph Westphal, Founder/CEO/Lead Investor, Alnylam/Momenta/Acceleron
9:55 am | Networking Break
10:20 am | Prioritizing the Pipeline
Christina Coughlin, CEO, Avacta Therapeutics
Andrew Hirsch, CEO, C4 Therapeutics
Robert Wild, Global Head, Oncology Search & Evaluation, Roche/Genentech
Richard Wilson, SVP, Primary Focus Lead, Genetic Regulation, Astellas
Moderator: Dipal Doshi, CEO, Entrada
10:50 am | Advancing Late-Stage Assets
Stewart Campbell, CEO, Novita Pharmaceuticals
Abe Ceesay, CEO, Rapport Therapeutics
Anna Kazanchyan, CEO, Saghmos Therapeutics
Neil Warma, CEO, ProMIS Neurosciences
Moderator: Robert Stanislaro, Senior Managing Director, FTI Consulting
11:20 am | Managing the Runway
Chris Loose, CEO, Progentos
Joanna Stanicka, CEO, Axonis
Joe Stauffer, CMO, PVP Labs
Leslie Williams, CEO, DaCapo Brainscience
Moderator: Rick Lundberg, CEO, Eikonizo
11:50 am | CEO Chat: What it Takes to Build a Great Company
Mathai Mammen, CEO, Parabilis
Jean-Frédéric Paulsen, CEO, Ferring Pharmaceuticals
Moderator: Seema Kumar, CEO, Cure.
12:15 pm | Networking Luncheon
1:15 pm | Targeted Licensing & Acquisitions
Matt Hefner, Global Head, BD, Kyowa Kirin
Jeff Landau, CEO, Stipple Bio
Karen Reeves, SVP, Investments & Head, Clinical Strategy, Ligand
Anjli Warner, Head, BD & New Product Planning, Arrowhead
Moderator: Zhen Su, CEO, Marengo Therapeutics
1:45 pm | Accelerating Drug Discovery
Aris Baras, SVP, Head, Regeneron Genetics Center
Jacob Hooker, CEO, Sensorium Therapeutics
Szabi Nagy, CEO, Turbine
Phil Vickers, CEO, Solu Therapeutics
Moderator: Kara Carter, CEO, Viraccio Therapeutics
2:15 pm | Developing High-Performing Teams
Laura Benjamin, CEO, Myris Therapeutics
Nenad Grmusa, CEO, DEM BioPharma
Wyatt McDonnell, CEO, Infinimmune
Quin Wills, CEO, Ochre Bio
Lilly Wollman, CEO, Synteny
Moderator: Isaac Klein, President, Dewpoint Therapeutics
2:50 pm | Networking Break
3:15 pm | Positioning for Commercial Success
Michael Bierl, CBO, Flatiron Health
Kabir Nath, CEO, COMPASS Pathways
Karin Shanahan, EVP, Chief Supply Chain & Operations Officer, BMS
Dennis Velasquez, CCO, Biorce
Moderator: Vikram Karnani, CEO, Collegium Pharmaceutical
3:45 pm | Fireside Chat
Fiona Marshall, President, Biomedical Research, Novartis
David Weinreich, Global Head, R&D, EMD Serono
Moderator: Sekhar Naik, CEO, MResult
4:05 pm | The Evolving Deal-Making Landscape
Al Beardsley, CEO, Cirius Therapeutics
Hannah England, Partner, Ropes & Gray
Murray McCutcheon, SVP, Partnering, AbCellera
Issei Tsukamoto, SVP, Head, BD, Astellas
Moderator: Philippe Lopes-Fernandes, CBO, Ipsen
4:35 pm | Evaluating Investment Risk
Ari Brettman, Senior Managing Director, Blackstone Life Science
Cailin McGurk, Managing Director, Morgan Stanley
Pini Orbach, Managing Partner & Head, Pharma, Arkin Capital
Jason Rhodes, Partner, Atlas Venture
Moderator: Aleks Radovic-Moreno, Partner, Longwood Fund
5:00 pm | Cocktail Reception
